Hatch Medical to Broker Chronic Total
Occlusion Device
Duluth, Georgia -- Hatch Medical, L.L.C., a medical device incubator and
technology brokerage firm, announced today that it has recently entered into an
agreement with Medical Miracles (Leeds, UK) to broker its patented and CE Marked
chronic total occlusion (CTO) device, POLAR™.
POLAR™ (Path Of Least Arterial Resistance) is a mechanical device that generates
reciprocal and lateral movements at the distal end of standard guidewires with
frequencies of 16 to 100 Hz. when passed through an angioplasty balloon
catheter, allowing clinicians to confidently cross occluded vessels.
Percutaneous interventions (PI) of a CTO remains one of the more difficult
technical challenges for interventional practitioners, despite the progress made
in the field of PI in the past decade. It has been estimated that CTOs are found
in one-third of patients with significant vascular disease. Failure to
revascularize a CTO often leaves the patient with either the more invasive
option of bypass graft surgery or continuing medical therapy, which may or may
not control their symptoms; neither is optimal.
In several published clinical studies which utilize the POLAR™ device in a
technique known as “vibrational angioplasty”, the device has proven to be both
expedient and efficacious. In one such study, seventy-eight patients with
chronic total occlusions (>3 months) that were resistant to conventional
techniques were treated with the POLAR™ device using a variety of standard
guidewires. The study found that lesions were successfully crossed in 67 (85.9%)
of these cases and antegrade flow was re-established in 59 (75.5%) patients,
causing one of the study participants to conclude, “The outcomes with this
low-cost device have been favorable.”
“We are pleased to be working with Medical Miracles’ POLAR™ device and believe
that it provides an efficacious and cost-effective solution to this chronic
clinical challenge,” commented Paul Gianneschi, Managing Principal of Hatch
Medical, L.L.C.
Barry Kaye, CEO of Medical Miracles added, “We are excited to be working with
Hatch Medical, as they have a long-standing history of successfully representing
companies through the license or sale of complex medical technologies.”
The POLAR™ device is available for licensing or acquisition to interested third
parties through an exclusive agreement with Hatch Medical.
For additional information on this, or other Hatch Medical, L.L.C. products and
services, e-mail the company at
info@hatchmedical.com. This release and additional news about Hatch
Medical can be obtained by visiting the company’s web site at:
http://www.hatchmedical.com.
Contact Paul Gianneschi, President and CEO, 770-982-6306, or Steve Hvozda,
Executive Vice President, Business Development 404-982-9994
Hatch Medical,
L.L.C.
Duluth, GA 30097
Phone: 770-476-9940
Facsimile: 770-476-7740
info@hatchmedical.com
© 2001 - 2008 Hatch Medical, L.L.C. - All rights reserved